肝脏微环境中各种细胞对肝星状细胞活化的影响

徐莹; 张定棋; 陈佳美; 刘伟; 刘平

doi:10.3969/j.issn.1001-5256.2019.02.042

肝脏微环境中各种细胞对肝星状细胞活化的影响

DOI: 10.3969/j.issn.1001-5256.2019.02.042

1. 上海中医药大学附属曙光医院上海中医药大学肝病研究所肝肾疾病病证教育部重点实验室上海市中医临床重点实验室
2. 上海中医药大学上海高校中医内科学E-研究院

基金项目:

国家自然科学基金重点项目(81530101);国家自然科学基金项目(81703681)；上海市青年科技英才扬帆计划资助项目(17YF1419800)；中国博士后科学基金资助项目(2016M601643)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1703
- HTML全文浏览量: 68
- PDF下载量: 411
- 被引次数: 0
出版历程
- 收稿日期: 2018-08-31
- 出版日期: 2019-02-20

Effect of various cells on the activation of hepatic stellate cells in liver microenvironment

Key Laboratory of Liver and Kidney Diseases ( Ministry of Education) & Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine

Research funding:

摘要

摘要: 肝纤维化是以肝脏细胞外基质过度沉积或疤痕组织过度增生为特点的动态病理过程。肝星状细胞(HSC)的活化被普遍认为是形成肝纤维化的中心环节。HSC的活化受到肝脏微环境中各种复杂因素的调控,包括理化刺激和细胞间交互作用等。肝脏内固有细胞及免疫细胞与HSC共同构建了一个复杂的调控系统,调控HSC的活化过程及其转归。主要介绍了肝脏微环境中各种细胞对HSC活化的调控作用,旨在为新型的抗纤维化诊疗手段的研究拓展思路。
- 肝硬化 /
- 脂细胞 /
- 细胞因子类 /
- 综述
Abstract: Liver fibrosis is a dynamic pathological process characterized by excessive deposition of extracellular matrix ( ECM) or hyperplasia of scar tissue. The activation of hepatic stellate cells ( HSCs) is generally considered the central link in the formation of liver fibrosis. HSC activation is regulated by various factors in liver microenvironment, including physical and chemical stimulations and intercellular interactions. Intrinsic cells and immune cells in the liver and HSCs together establish a complex regulatory system to regulate HSC activation and regression. This article introduces the regulatory effect of the cells in liver microenvironment on HSC activation, in order to expand thinking for the research on new diagnosis and treatment methods for liver fibrosis.
- liver cirrhosis /
- adipocytes /
- cytokines /
- review

HTML全文

参考文献(58)

[1]ELLIS EL, MANN DA.Clinical evidence for the regression of liver fibrosis[J].J Hepatol, 2012, 56 (5) :1171-1180.

[2]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open-label follow-up study[J].Lancet, 2013, 381 (9865) :468-475.

[3]PUCHE JE, SAIMAN Y, FRIEDMAN SL.Hepatic stellate cells and liver fibrosis[J].Compr Physiol, 2013, 3 (4) :1473-1492.

[4]ZHANG DY, GOOSSENS N, GUO J, et al.A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection[J].Gut, 2016, 65 (10) :1754-1764.

[5]WREE A, EGUCHI A, MCGEOUGH MD, et al.NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice[J].Hepatology, 2014, 59 (3) :898-910.

[6]KOUI Y, KIDO T, ITO T, et al.An in vitro human liver model by ipsc-derived parenchymal and non-parenchymal cells[J].Stem Cell Rep, 2017, 9 (2) :490-498.

[7]JIANG JX, MIKAMI K, VENUGOPAL S, et al.Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways[J].J Hepatol, 2009, 51 (1) :139-148.

[8]DELEVE LD, WANG X, GUO Y.Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence[J].Hepatology, 2008, 48 (3) :920-930.

[9]XIE G, WANG X, WANG L, et al.Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats[J].Gastroenterology, 2012, 142 (4) :918-927.

[10]DING BS, CAO Z, LIS R, et al.Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis[J].Nature, 2014, 505 (7481) :97-102.

[11]WANG L, BAI G, CHEN F, et al.Human bone marrow mesenchymal stem cells (BMSCs) suppress hepatic stellate cells (HSCs) proliferation by inhibiting the ubiquitylation of p27[J].Biochem Cell Biol, 2017, 95 (6) :18-24.

[12]SONG F, XIANG YY, HUANG M, et al.Experimental study on inhibiting EMT of rabbit bile duct epithelial cells by paclitaxel chitosan membrane[J].J Kunming Med Univ, 2017, 38 (12) :5-11. (in Chinese) 宋飞, 向盈盈, 黄明, 等.紫杉醇壳聚糖缓释膜抑制兔胆管上皮细胞EMT的实验[J].昆明医科大学学报, 2017, 38 (12) :5-11.

[13]SCHWER CI, STOLL P, GOEBEL U, et al.Effects of hydrogen sulfide on rat pancreatic stellate cells[J].Pancreas, 2012, 41 (1) :74-79.

[14]OMENETTI A, YANG L, LI YX, et al.Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation[J].Lab Invest, 2007, 87 (5) :499-514.

[15]ZHAO WH, WANG YH, CONG M.Regulatory effect of transforming growth factor-βon activation of hepatic stellate cells[J].JClin Hepatol, 2016, 32 (11) :2195-2198. (in Chinese) 赵卫华, 王燕红, 丛敏.转化生长因子β对肝星状细胞活化的调控作用[J].临床肝胆病杂志, 2016, 32 (11) :2195-2198.

[16]REN CZ, HAO LS.Signal transduction involved in activation of hepatic stellate cells[J].J Clin Hepatol, 2015, 31 (3) :452-456. (in Chinese) 任昌镇, 郝礼森.肝星状细胞活化过程中的信号转导[J].临床肝胆病杂志, 2015, 31 (3) :452-456.

[17]MARRONE G, SHAH VH, GRACIASANCHO J.Sinusoidal communication in liver fibrosis and regeneration[J].J Hepatol, 2016, 65 (3) :608-617.

[18]KUROKAWA T, ZHENG YW, OHKOHCHI N.Novel functions of platelets in the liver[J].J Gastroenterol Hepatol, 2016, 31 (4) :745-751.

[19]YOSHIDA S, IKENAGA N, LIU SB, et al.Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice[J].Gastroenterology, 2014, 147 (6) :1378-1392.

[20]SONG P, ZHANG J, ZHANG Y, et al.Hepatic recruitment of CD11b+Ly6C+inflammatory monocytes promotes hepatic ischemia/reperfusion injury[J].Int J Mol Med, 2018, 41 (2) :935-945.

[21]KARLMARK KR, WEISKIRCHEN R, ZIMMERMANN HW, et al.Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis[J].Hepatology, 2009, 50 (1) :261-274.

[22]MIURA K, YANG L, VAN RN, et al.Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2[J].Am J Physiol Gastrointest Liver Physiol, 2012, 302 (11) :g1310-g1321.

[23]PRADERE JP, KLUWE J, MINICIS SD, et al.Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice[J].Hepatology, 2013, 58 (4) :1461-1473.

[24]SEKI E, DE MINICIS S, GWAK GY, et al.CCR1 and CCR5promote hepatic fibrosis in mice[J].J Clin Invest, 2009, 119 (7) :1858-1870.

[25]HEINRICHS D, BERRES ML, NELLEN A, et al.The chemokine CCL3 promotes experimental liver fibrosis in mice[J].PLo S One, 2013, 8 (6) :e66106.

[26]BERRES ML, KOENEN RR, RUELAND A, et al.Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice[J].J Clin Invest, 2010, 120 (11) :4129-4140.

[27]WENG SY, WANG XY, VIJAYAN S, et al.IL-4 receptor alpha signaling through macrophages differentially regulates liver fibrosis progression and reversal[J].EBio Medicine, 2018, 29:92-103.

[28]HOU SM, HOU CH, LIU JF.CX3CL1 promotes MMP-3 production via the CX3CR1, c-Raf, MEK, ERK, and NF-κBsignaling pathway in osteoarthritis synovial fibroblasts[J].Arthritis Res Ther, 2017, 19 (1) :282.

[29]AOYAMA T, INOKUCHI S, BRENNER DA, et al.CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice[J].Hepatology, 2010, 52 (4) :1390-1400.

[30]KANTARI-MIMOUN C, CASTELLS M, KLOSE R, et al.Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis[J].Hepatology, 2015, 61 (6) :2042-2055.

[31]TEDESCO D, THAPA M, GUMBER S, et al.CD4+Foxp3+Tcells promote aberrant immunoglobulin G production and maintain CD8+T-cell suppression during chronic liver disease[J].Hepatology, 2017, 65 (2) :661-677.

[32]WU J, GUO J, CAO Q, et al.Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway[J].Oncol Lett, 2017, 13 (2) :770-776.

[33]WEAVER CT, HATTON RD, MANGAN PR, et al.IL-17 family cytokines and the expanding diversity of effector T cell lineages[J].Annu Rev Immunol, 2007, 25 (25) :821-852.

[34]CACHEM FC, DIAS AS, MONTEIROC, et al.The proportion of different IL-17-producing T cell subsets is associated with liver fibrosis in chronic hepatitis C[J].Immunology, 2017, 151 (2) :546-552.

[35]RONCAROLO MG, BATTAGLIA M.Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans[J].Nat Rev Immunol, 2007, 7 (8) :585-598.

[36]SAKAKI M, HIROISHI K, BABA T, et al.Intrahepatic status of regulatory T cells in autoimmune liver diseases and chronic viral hepatitis[J].Hepatol Res, 2008, 38 (4) :354-361.

[37]CHOU HS, HSIEH CC, YANG HR, et al.Hepatic stel ate cells regulate immune response by way of induction of myeloid suppressor cells in mice[J].Hepatology, 2011, 53 (3) :1007-1019.

[38]DANGI A, SUMPTER TL, KIMURA S, et al.Selective expansion of allogeneic regulatory T cells by hepatic stellate cells:Role of endotoxin and implications for allograft tolerance[J].JImmunol, 2012, 188 (8) :3667-3677.

[39]PENG Y, LI Y, HE Y, et al.The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis:Asystematic review[J].Expert Rev Gastroenterol Hepatol, 2018, 12 (5) :332-338.

[40]EMANUELE E, BERTONA M.Interleukin-17-targeted treatment of alcoholic liver disease[J].Hepatology, 2009, 50 (1) :329-330.

[41]JEONG WI, PARK O, GAO B.Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis[J].Gastroenterology, 2008, 134 (1) :248-258.

[42]PENG Y, YANG T, HUANG K, et al.Salvia miltiorrhiza ameliorates liver fibrosis by activating hepatic natural killer cells in vivo and in vitro[J].Front Pharmacol, 2018, 14 (1) :48-54.

[43]POCKROS PJ, JEFFERS L, AFDHAL N, et al.Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis[J].Hepatology, 2007, 45 (3) :569-578.

[44]KRIZHANOVSKY V, YON M, DICKINS RA, et al.Senescence of activated stellate cells limits liver fibrosis[J].Cell, 2008, 134 (4) :657-667.

[45]GAO B, RADAEVA S, PARK O.Liver natural killer and natural killer T cells:Iunobiology and emerging roles in liver diseases[J].J Leukoc Biol, 2009, 86 (3) :513-528.

[46]KRMER B, KRNER C, KEBSCHULL M, et al.Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis[J].Hepatology, 2012, 56 (4) :1201-1213.

[47]JEONG WI, PARK O, SUH YG, et al.Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice[J].Hepatology, 2011, 53 (4) :1342-1351.

[48]GAO B, JEONG WI, TIAN Z.Liver:An organ with predominant innate immunity[J].Hepatology, 2008, 47 (2) :729-736.

[49]BOND NG, KAUR A.NKT cells:Bridging innate and adaptive immunity[M].Encyclopedia of AIDS, 2016.

[50]WEHR A, BAECK C, HEYMANN F, et al.Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis[J].J Immunol, 2013, 190 (10) :5226-5236.

[51]JIN Z, RUI SUN, WEI H, et al.Accelerated liver fibrosis in hepatitis B virus transgenic mice:Involvement of natural killer T cells[J].Hepatology, 2011, 53 (1) :219-229.

[52]WANG H, YIN S.Natural killer T cells in liver injury, inflammation and cancer[J].Expert Rev Gastroenterol Hepatol, 2015, 9 (8) :1077-1085.

[53]CRISPE IN.The liver as a lymphoid organ[J].Annu Rev Immunol, 2009, 27 (27) :147-163.

[54]CONNOLLY MK, BEDROSIAN AS, MALLEN-ST CJ, et al.In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha[J].J Clin Invest, 2009, 119 (11) :3213-3225.

[55]COLLIN M, BIGLEY V.Human dendritic cell subsets:An update[J].Immunology, 2018, 119 (15) :301-307.

[56]THAPA M, CHINNADURAI R, VELAZQUEZ VM, et al.Liver fibrosis occurs through dysregulation of My D88-dependent innate B-cell activity[J].Hepatology, 2015, 61 (6) :2067-2079.

[57]TRAUTWEIN C, FRIEDMAN SL, SCHUPPAN D, et al.Hepatic fibrosis:Concept to treatment[J].J Hepatol, 2015, 62 (1) :s15-s24.

[58]LEE YA, WALLACE MC, FRIEDMAN SL.Pathobiology of liver fibrosis:A translational success story[J].Gut, 2015, 64 (5) :830-841.

施引文献

资源附件(0)

访问统计